Where is Bulgaria on the path to meeting the global goals for the elimination of hepatitis B and C?

Prof. Genka Petrova

Department of "Organization and Economics of Pharmacy", Faculty of Pharmacy, Medical University - Sofia

Prof. Dr. Krassimir Antonov, MD

Chairman of the Bulgarian Society of Gastroenterology, Gastrointestinal Endoscopy and Abdominal Ultrasound

Prof. Dr. Krassimir Antonov, MD, is one of the most prominent hepatologists in Bulgaria. He acquired the specialties Internal Medicine and Gastroenterology and Dietetics in 1995 and 2000.
In 2000 he defended his dissertation on "Study of the replication of hepatitis Delta virus (HDV) in the evolution and treatment of chronic Delta infection." and obtains the educational and scientific degree of Doctor. In 2010 he became a doctor of medical sciences with a dissertation on "Chronic HCV infection - characteristics and features of treatment." Since 2012 he has been a professor of gastroenterology. He specializes in the Institute of Liver Studies, King’s College, London. Prof. Antonov is the author of 98 scientific articles, reviews, participations in collections and textbooks in Bulgarian and English; 108 scientific communications at national and international congresses and conferences.
Chairman of the Bulgarian Society of Gastroenterology, Gastrointestinal Endoscopy and Abdominal Ultrasound; member of the European Association for the Study of the Liver (EASL). Prof. Antonov is responsible for the diagnosis and treatment of chronic viral hepatitis at the Clinic of Gastroenterology at St. Ivan Rilski University Hospital, Sofia.

George Kalamitsis

Chairman of the Greek patient organization Prometheus and Liver Patients International

Chairman of the Greek patient organization Prometheus and Liver Patients International. Member of the Monitoring Committee for the implementation of the National Action Plan for Hepatitis C at the Greek Ministry of Health, as well as of the Public Policy Association for Hepatitis B and C. From 2014 to 2016 he was part of the board of the World Hepatitis Alliance.
In his work, George Kalamitsis is committed to raising awareness, preventing and supporting vulnerable groups affected by liver disease, with a focus on patients' rights.

Assoc. Prof. Maria Dimitrova

Department of "Organization and Economics of Pharmacy", Faculty of Pharmacy, Medical University - Sofia

Silvana Lesidrenska

Chairman of HepActive Association

Dr. Radin Tsonev, MD

Chief Assistant at the Clinic of Gastroenterology-Acibadem City Clinic-MHAT-Tokuda-Sofia

Homie Razavi

Founder and director of the Center for Disease Analysis Foundation

Homie A. Razavi is the founder and managing director at the Center for Disease Analysis Foundation. Since 2008, Homie has led a team of epidemiologists and modellers to quantify the epidemiology of hepatitis, forecast the future disease burden and help countries develop national strategies. His team has been responsible for the development of a number of mathematical models currently used by countries to develop intervention strategies for hepatitis B & C. In addition, his team has developed the Polaris Observatory, which collects and reports HCV, HBV, and HDV epidemiology, and disease burden and treatment rates for all countries. He has a broad background, which includes basic research, commercial development, portfolio management, and decision analysis. He has a Ph.D. in Organic Chemistry from the University of Colorado and an MBA from Washington University.

Assoc. Dr. Mihail Okoliyski

HWO at World Health Organization

Assoc. Prof. Dr. Tonka Varleva, Ph.D.

Director of the Health Promotion, Disease and Addiction Prevention Directorate, Ministry of Health